Skip to main content
Fig. 6 | Journal of Translational Medicine

Fig. 6

From: SGLT2 inhibitors improve kidney function and morphology by regulating renal metabolic reprogramming in mice with diabetic kidney disease

Fig. 6

Empagliflozin ameliorated serum metabolism. A Venn plot showing 37 Empa-altered metabolites from 174 serum DEMs (|fold change|> 1.5, and p < 0.05). B The Venn plot shows the intersection of renal metabolites and serum metabolites altered by Empa. C Scatter plot showing the Pearson’s correlation between serum and kidney altered metabolites. D Pie charts showing the Chi-squared test (or Fisher exact test) of the percentage changes in the category of metabolites for the 194 serum’s DEMs in db/db mice and the 37 Empa-altered metabolites. E Heatmap depicting the expression levels of the 37 serum metabolites altered by empagliflozin. Those 37 metabolites were classified for 6 categories according to the HMDB database. Among them, the metabolites belonging to ‘amnio acids and derivatives’ were further divided into five different types and calculated its percentage. F KEGG pathway analysis based on the relative intensity levels of 37 Empa-altered metabolites in the serum (hypergeometric test, p < 0.05; Impact > 0.1). G Activity state of enriched metabolic pathways for 37 Empa-altered metabolites in the serum

Back to article page